On September 22, 2022, the Board of Directors of bluebird bio, Inc. appointed Katherine Breedis to serve as the Company’s interim Chief Financial Officer, succeeding Jason F. Cole, the Company’s current Chief Strategy and Financial Officer. Ms. Breedis’ appointment will be effective upon Mr. Cole’s departure from the Company on October 14, 2022 (the Transition Date). Ms. Breedis, age 59, has served as a Chief Financial Officer Consultant at Danforth Advisors, LLC (Danforth), a strategic finance and operations firm with a focus on life sciences companies, since July 2021, where she provides interim chief financial officer and strategic business development consulting services to public and private U.S.-based and international biotechnology companies.
She has also served as a Chief Financial Officer and Corporate Strategy Consultant at Independent Biotechnology Consulting since April 2019. Prior to that, Ms. Breedis served as the Chief Financial Officer of MeiraGTx from October 2018 to April 2019, and as Managing Director of Stifel Nicolaus from October 2015 to July 2017. Prior to joining Stifel Nicolaus, Ms. Breedis served in corporate strategy and business development roles with Pfizer Inc. and Eli Lilly & Company, respectively.
In addition, Ms. Breedis was a senior analyst with Schroders, Goldman Sachs and Citigroup Asset Management and held several other senior positions in corporate finance and merchant banking with GE Capital and Creditanstalt-Bankverein. Ms. Breedis received a B.A. in Economics and Art History from Wheaton College and is a Chartered Financial Analyst and Chartered Market Technician.